Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | March 15, 2010 | March 16, 2010 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date March 15, 2010 · Filed March 16, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2010-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2010-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2010-03-15 · Sale · Disposed 10,000 · Balance 0 F1: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52). F3: Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $38.44 · Expires 2010-05-31 | Direct | 0 |
Reported balance
After 2010-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2010-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F4: Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52).
F3: Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $38.44 | $0.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · derivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2010-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $43.10 | $431,000.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52). F3 · price: Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $38.44 | $384,400.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 18:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0000875320-09-000042 · edgar.xml · derivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2019-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| June 01, 2008 Filed Jun 2, 2008 20:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0000875320-08-000040 · edgar.xml · derivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,333 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · derivative · entry 11 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.16 | $9,044.28 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 10 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.99 | $8,987.67 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 9 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.84 | $8,964.56 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 8 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.75 | $8,907.75 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 7 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.71 | $8,894.43 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 6 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 666 | $26.68 | $17,768.88 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 5 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.66 | $8,904.44 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 4 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,332 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.54 | $8,864.36 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.40 | $8,791.20 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $14.20 | $47,328.60 |
DisclosureSEC source: 0000875320-08-000034 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,333 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · derivative · entry 10 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.68 | $9,217.44 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 9 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 667 | $27.47 | $18,322.49 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 8 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.73 | $9,234.09 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 7 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 667 | $27.71 | $18,482.57 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 6 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.61 | $9,194.13 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 5 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.59 | $9,187.47 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 4 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.58 | $9,184.14 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $27.50 | $9,185.00 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,999 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $14.20 | $47,328.60 |
DisclosureSEC source: 0000875320-08-000028 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,334 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · derivative · entry 12 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $27.70 | $9,251.80 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 11 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.46 | $8,238.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 10 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.27 | $8,181.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 9 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $27.19 | $13,595.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 8 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.14 | $2,714.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 7 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.13 | $5,426.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 6 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.08 | $8,124.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 5 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.07 | $8,121.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 4 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,034 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.03 | $8,109.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $27.00 | $18,900.00 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,634 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,334 | $14.20 | $47,342.80 |
DisclosureSEC source: 0000875320-08-000021 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 16:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000062 · edgar.xml · derivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| April 10, 2007 Filed Apr 11, 2007 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0000875320-07-000037 · edgar.xml · derivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2007-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1997. Read SEC document |
| April 10, 2007 Filed Apr 11, 2007 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $32.36 | $323,600.00 |
DisclosureSEC source: 0000875320-07-000037 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved trading plan established under Rule 10b5-1. Read SEC document |
| April 10, 2007 Filed Apr 11, 2007 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $19.78 | $197,800.00 |
DisclosureSEC source: 0000875320-07-000037 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2006 Filed Jun 2, 2006 17:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000050 · edgar.xml · derivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 20,000 shares Expires 2016-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · derivative · entry 9 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 10,000 shares Expires 2015-05-31 F3 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2005. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · derivative · entry 8 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 7,500 shares Expires 2014-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2004. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · derivative · entry 7 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires 2009-05-31 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1999. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $35.19 | $351,900.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · nonDerivative · entry 6 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $13.32 | $133,200.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · nonDerivative · entry 5 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $35.19 | $263,925.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · nonDerivative · entry 4 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $9.09 | $68,175.00 |
DisclosureSEC source: 0000875320-06-000019 · edgar.xml · nonDerivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.